Loading...
Ocugen, Inc.
OCGN•NASDAQ
Healthcare
Biotechnology
$0.93
$-0.10(-10.13%)
Ocugen, Inc. (OCGN) Financial Performance & Statements
Review Ocugen, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns to understand its financial health and growth.
Revenue Growth
-32.82%
↓ 32.82%
Operating Income Growth
16.44%
↑ 16.44%
Net Income Growth
14.31%
↑ 14.31%
Operating Cash Flow Growth
32.09%
↑ 32.09%
Operating Margin
-1261.43%
↓ 1261.43%
Gross Margin
100.00%
↑ 100.00%
Net Profit Margin
-1271.12%
↓ 1271.12%
ROE
-223.00%
↓ 223.000%
ROIC
-119.90%
↓ 119.90%
Ocugen, Inc. (OCGN) Financial Statements
Explore quarterly and annual reports including balance sheet, income statement, cash flow for Ocugen, Inc. stock.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $764000.00 | $1.14M | $1.14M | $1.01M |
| Cost of Revenue | $598000.00 | $0.00 | $8.90M | $179000.00 |
| Gross Profit | $166000.00 | $1.14M | -$7.76M | $835000.00 |
| Gross Profit Ratio | $0.22 | $1.00 | -$6.80 | $0.82 |
| R&D Expenses | $8.29M | $8.11M | $8.90M | $6.83M |
| SG&A Expenses | $6.31M | $6.28M | $7.69M | $6.22M |
| Operating Expenses | $14.60M | $14.39M | $16.59M | $13.05M |
| Total Costs & Expenses | $14.60M | $14.39M | $16.59M | $13.23M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $598000.00 | $613000.00 | $578000.00 | $179000.00 |
| EBITDA | -$13.24M | -$12.64M | -$14.87M | -$12.04M |
| EBITDA Ratio | -$17.33 | -$11.13 | -$13.03 | -$11.87 |
| Operating Income | -$13.84M | -$13.25M | -$15.45M | -$12.22M |
| Operating Income Ratio | -$18.12 | -$11.67 | -$13.54 | -$12.05 |
| Other Income/Expenses (Net) | -$40000.00 | $282000.00 | $169000.00 | $292000.00 |
| Income Before Tax | -$13.88M | -$12.97M | -$15.28M | -$11.92M |
| Income Before Tax Ratio | -$18.17 | -$11.42 | -$13.39 | -$11.76 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$13.88M | -$12.97M | -$15.28M | -$11.92M |
| Net Income Ratio | -$18.17 | -$11.42 | -$13.39 | -$11.76 |
| EPS | -$0.05 | -$0.05 | -$0.04 | -$0.05 |
| Diluted EPS | -$0.05 | -$0.05 | -$0.04 | -$0.05 |
| Weighted Avg Shares Outstanding | $290.92M | $278.17M | $257.35M | $257.23M |
| Weighted Avg Shares Outstanding (Diluted) | $290.92M | $278.17M | $257.35M | $257.23M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan